💊
Jaypirca
pirtobrutinib
Lymfom, mantelcells-
✅ Auktoriserad
✅
Inga aktiva aviseringar
Denna medicin har inga pågående brister, säkerhetsbrev eller återkallelser.
Vad det används till
Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have been previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor. Jaypirca as monotherapy is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) who have been previously treated with a BTK inhibitor.
⚠️ Patientsäkerhet
No
Officiell EMA-sida
https://www.ema.europa.eu/en/medicines/human/EPAR/jaypirca